Latest News

Dow Jones Newswires: AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval

0

AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

The pharmaceutical company
AZN,
-0.15%

said Enhertu has been recommended by the EU’s Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

FA Center: Why the 60/40 portfolio is a worthy strategy even though stocks and bonds are weak

Previous article

: Four of the five fingers of death are squeezing world output, economist warns

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News